Abstract
New therapies based on the targeting of signal pathways (such as VHL/HIF-1) common to most renal cell carcinomas (RCC), have greatly improved the outlook for sufferers of this disease. Given the growing reputation of many microRNAs (miRNAs) as both tumor suppressors and oncogenes, the measurement and manipulation of these small nucleotides in RCC patients may provide yet another valuable advance in renal cancer diagnosis and treatment. The present review summarizes the current literature on the role of microRNAs in RCC development and progression emphasizing the interaction of specific miRNAs with both oncogenic and tumor suppressor pathways of particular importance in renal cancer.
Keywords: c-MET, cancer, hypoxia-inducible factor (HIF), mammalian target of rapamycin (mTOR), miRNA, renal cell carcinoma, vascular endothelial growth factor (VEGF), Von Hippel-Lindau protein (VHL).
MicroRNA
Title:MicroRNAs in Renal Cell Carcinoma
Volume: 4 Issue: 1
Author(s): Donald F. Sellitti and Sonia Q. Doi
Affiliation:
Keywords: c-MET, cancer, hypoxia-inducible factor (HIF), mammalian target of rapamycin (mTOR), miRNA, renal cell carcinoma, vascular endothelial growth factor (VEGF), Von Hippel-Lindau protein (VHL).
Abstract: New therapies based on the targeting of signal pathways (such as VHL/HIF-1) common to most renal cell carcinomas (RCC), have greatly improved the outlook for sufferers of this disease. Given the growing reputation of many microRNAs (miRNAs) as both tumor suppressors and oncogenes, the measurement and manipulation of these small nucleotides in RCC patients may provide yet another valuable advance in renal cancer diagnosis and treatment. The present review summarizes the current literature on the role of microRNAs in RCC development and progression emphasizing the interaction of specific miRNAs with both oncogenic and tumor suppressor pathways of particular importance in renal cancer.
Export Options
About this article
Cite this article as:
Sellitti F. Donald and Doi Q. Sonia, MicroRNAs in Renal Cell Carcinoma, MicroRNA 2015; 4 (1) . https://dx.doi.org/10.2174/2211536604666150713105247
DOI https://dx.doi.org/10.2174/2211536604666150713105247 |
Print ISSN 2211-5366 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5374 |
Call for Papers in Thematic Issues
Modulatory Roles of Non-coding RNAs in cancer therapy
This thematic issue aims to elucidate the most recent research on ncRNAs in CRCs and discuss the importance and difficulties that may arise in applying this tool on a regular clinical basis.read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Endothelin Receptor Antagonists: A New Therapeutic Option for Improving the Outcome after Solid Organ Transplantation?
Current Vascular Pharmacology Breaking the DNA Damage Response via Serine/Threonine Kinase Inhibitors to Improve Cancer Treatment
Current Medicinal Chemistry Personalized Medicine in Oncology: A Personal View with Myths and Facts
Current Clinical Pharmacology Histopathological Determinants of Tumor Resistance: A Special Look to the Immunohistochemical Expression of Carbonic Anhydrase IX in Human Cancers
Current Medicinal Chemistry Proteomic Study of the Mechanism of Talin-C as an Inhibitor of HIV Infection
Current Proteomics Cardiac Toxicities of Antiangiogenic Therapies
Current Angiogenesis (Discontinued) mTOR Inhibition and the Tumor Vasculature
Current Angiogenesis (Discontinued) Clinical Proteomics in Application to Predictive Diagnostics and Personalized Treatment of Diabetic Patients
Current Proteomics The Genetic Basis of New Treatment Modalities in Melanoma
Current Drug Targets Phytochemicals for Breast Cancer Therapy: Current Status and Future Implications
Current Cancer Drug Targets Arsenic trioxide Alters the MicroRNA Expression Profile of U87 glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Molecular Evidence of Compound Kushen Injection Against Lung Cancer: A Network Pharmacology-Based Investigation from Western Medicine to Traditional Medicine
Anti-Cancer Agents in Medicinal Chemistry New Insights into the Regulation of Liver Inflammation and Oxidative Stress
Mini-Reviews in Medicinal Chemistry Conjugates of Natural Compounds with Nitroxyl Radicals as a Basis for Creation of Pharmacological Agents of New Generation
Current Medicinal Chemistry An Overview of Synthesis of Indole Alkaloids and Biological Activities of Secondary Metabolites Isolated from Hyrtios Species
Mini-Reviews in Medicinal Chemistry Chronopharmacology and Antimicrobial Therapeutics
Current Clinical Pharmacology Vasopressin in Health and Disease with a Focus on Affective Disorders
Central Nervous System Agents in Medicinal Chemistry Cytokines as Anti-Angiogenic Agents in Haematological Malignancies
Current Cancer Drug Targets Epigenetic Regulators Governing Cancer Stem Cells and Epithelial- Mesenchymal Transition in Oral Squamous Cell Carcinoma
Current Stem Cell Research & Therapy Bone Morphogenetic Proteins and its Receptors; Therapeutic Targets in Cancer Progression and Bone Metastasis?
Current Pharmaceutical Design